Guru P. Sonpavde, MD

Guru P. Sonpavde, MD, is the medical director for Genitourinary (GU) Oncology, assistant director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at AdventHealth Cancer Institute.

Articles

Dr Sonpavde on the Ongoing Investigation of V940 Plus Pembrolizumab in High-Risk MIBC

March 26th 2025

Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.

Dr Sonpavde on the AMBASSADOR Trial in Muscle-Invasive Urothelial Cancer

December 4th 2024

Guru P. Sonpavde, MD, discusses the AMBASSADOR trial of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma.

Dr Sonpavde on the Implications of the NIAGARA Trial Regimen in Bladder Cancer

November 27th 2024

Guru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.

Dr Sonpavde on Early Data With Sacituzumab Govitecan Plus Ipilimumab/Nivolumab in Urothelial Cancer

October 7th 2024

Guru P. Sonpavde, MD, discusses initial data from a phase 1/2 trial of sacituzumab govitecan plus ipilimumab and nivolumab in metastatic urothelial cancer.

The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma

January 30th 2024

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Dr Sonpavde on the Efficacy of Frontline Nivolumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

November 29th 2023

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Dr Sonpavde on the Importance of Utilizing Precision Medicine in Bladder Cancer

August 22nd 2023

Guru P. Sonpavde, MD, discusses the importance of utilizing precision medicine in bladder cancer, and highlights the rationales and designs of the ongoing phase 3 EV-302 and AMBASSADOR trials.

Dr Sonpavde on the Future of Treating Bladder Cancer

August 14th 2023

Guru P. Sonpavde, MD, discusses the future of bladder cancer treatment, including potential novel targets and further research with immunotherapy and antibody-drug conjugates.

Dr Sonpavde on the Results of the SWOG S1011 Trial in MIBC

July 31st 2023

Guru P. Sonpavde, MD, discusses results from the phase 3 SWOG S1011 trial conducted in patients with muscle-invasive bladder cancer.

Dr. Sonpavde on the Investigation of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

October 31st 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde

February 19th 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

New Strategies Enhance Care in mUC

November 25th 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

August 24th 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Dr. Sonpavde on Combining VEGF/PD-1 Inhibitors in Metastatic Urothelial Carcinoma

August 14th 2020

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer

November 2nd 2019

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Dr. Sonpavde on Neoadjuvant Immunotherapy in Bladder Cancer

October 26th 2019

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

Dr. Sonpavde on Enfortumab Vedotin Data in Urothelial Cancer

October 9th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Sonpavde on Immunotherapy After Progression in Advanced Bladder Cancer

September 10th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Dr. Sonpavde on Emerging Immunotherapy Approaches in Bladder Cancer

July 24th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses emerging immunotherapy approaches in bladder cancer.

Dr. Sonpavde on the Biggest Challenges in Bladder Cancer

July 17th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the biggest challenges in the field of bladder cancer.